Table of Contents
René Belder, MD
PPT Slide
Pravachol Extensive Worldwide Safety Experience
Special Safety Considerations For OTC Use
PPT Slide
Pravachol: No Clinically Relevant Pharmacokinetic Drug Interactions
Lack of Drug Interactions with Pravastatin
Safety Considerations Musculoskeletal
Rhabdomyolysis
Rhabdomyolysis Reported During Pravastatin Use
Post-Marketing Cases of Rhabdomyolysis Show No Apparent Relationship to Dose or Country
Rhabdomyolysis Summary
PPT Slide
Pravachol Liver Monitoring Label History: Reduction of Monitoring Requirements Over Time
No Statistically Significant Differences Between Pravastatin and Placebo in Abnormalities of ALT
No Statistically Significant Differences Between Pravastatin and Placebo in Abnormalities of ALT in Subjects with an Elevated Baseline Value
Pravachol Hepatobiliary Safety
PPT Slide
PPT Slide
Pravachol Safety Considerations: Pregnancy
PPT Slide
|